The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM

The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM - The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036560

Enrollment

Registered

2019-05-01

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD/NASH

Interventions

Patients were treated with Canagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Taking alcohol less than 20g/day 2. NAFLD was diagnosed by liver biopsy or abdominal ultrasonography

Exclusion criteria

Exclusion criteria: 1. pregnant woman or lactating mother 2. poorly controlled heart failure 3. poorly controlled hypertension or diabetes 4. severe renal disorder 5. decompensated liver cirrhosis 6. other liver diseases, including autoimmune hepatitis, primary biliary cholangitis and alcoholic hepatitis, liver failure 7. positive result for hepatitis C antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 8. hypercarcemia 9. hyperparathyroidism 10. Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
The liver function after Canagliflozin administration for 24weeks	—

Secondary

Measure	Time frame
1. The lipid and glycometabolism after Canagliflozin administration for 24weeks 2. The safety of Canagliflozin	—

Countries

Japan

Contacts

Public ContactYuji Yoshida

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

yuji-y@nms.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026